TY - JOUR
T1 - Clinical Diagnosis and Early Medical Management for Endometriosis
T2 - Consensus from Asian Expert Group
AU - Kim, Mee Ran
AU - Chapron, Charles
AU - Römer, Thomas
AU - Aguilar, Angela
AU - Chalermchockcharoenkit, Amphan
AU - Chatterjee, Siddharta
AU - Dao, Le Thi Anh
AU - Fong, Yoke Fai
AU - Hendarto, Hendy
AU - Hidayat, Syarief Taufik
AU - Khong, Su Yen
AU - Ma, Li
AU - Kumar, Pratap
AU - Primariawan, Relly Yanuari
AU - Siow, Anthony
AU - Sophonsritsuk, Areepan
AU - Devi Thirunavukarasu, Ramani
AU - Thuong, Bui Chi
AU - Yen, Chih Feng
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - This work provides consensus guidance regarding clinical diagnosis and early medical management of endometriosis within Asia. Clinicians with expertise in endometriosis critically evaluated available evidence on clinical diagnosis and early medical management and their applicability to current clinical practices. Clinical diagnosis should focus on symptom recognition, which can be presumed to be endometriosis without laparoscopic confirmation. Transvaginal sonography can be appropriate for diagnosing pelvic endometriosis in select patients. For early empiric treatment, management of women with clinical presentation suggestive of endometriosis should be individualized and consider presentation and therapeutic need. Medical treatment is recommended to reduce endometriosis-associated pelvic pain for patients with no immediate pregnancy desires. Hormonal treatment can be considered for pelvic pain with a clinical endometriosis diagnosis; progestins are a first-line management option for early medical treatment, with oral progestin-based therapies generally a better option compared with combined oral contraceptives because of their safety profile. Dienogest can be used long-term if needed and a larger evidence base supports dienogest use compared with gonadotropin-releasing hormone agonists (GnRHa) as first-line medical therapy. GnRHa may be considered for first-line therapy in some specific situations or as short-term therapy before dienogest and non-steroidal anti-inflammatory drugs as add-on therapy for endometriosis-associated pelvic pain.
AB - This work provides consensus guidance regarding clinical diagnosis and early medical management of endometriosis within Asia. Clinicians with expertise in endometriosis critically evaluated available evidence on clinical diagnosis and early medical management and their applicability to current clinical practices. Clinical diagnosis should focus on symptom recognition, which can be presumed to be endometriosis without laparoscopic confirmation. Transvaginal sonography can be appropriate for diagnosing pelvic endometriosis in select patients. For early empiric treatment, management of women with clinical presentation suggestive of endometriosis should be individualized and consider presentation and therapeutic need. Medical treatment is recommended to reduce endometriosis-associated pelvic pain for patients with no immediate pregnancy desires. Hormonal treatment can be considered for pelvic pain with a clinical endometriosis diagnosis; progestins are a first-line management option for early medical treatment, with oral progestin-based therapies generally a better option compared with combined oral contraceptives because of their safety profile. Dienogest can be used long-term if needed and a larger evidence base supports dienogest use compared with gonadotropin-releasing hormone agonists (GnRHa) as first-line medical therapy. GnRHa may be considered for first-line therapy in some specific situations or as short-term therapy before dienogest and non-steroidal anti-inflammatory drugs as add-on therapy for endometriosis-associated pelvic pain.
KW - diagnosis
KW - endometriosis
KW - medical management
UR - http://www.scopus.com/inward/record.url?scp=85144646623&partnerID=8YFLogxK
U2 - 10.3390/healthcare10122515
DO - 10.3390/healthcare10122515
M3 - Review article
AN - SCOPUS:85144646623
SN - 2227-9032
VL - 10
JO - Healthcare (Switzerland)
JF - Healthcare (Switzerland)
IS - 12
M1 - 2515
ER -